The current treatments for CRS caused by CAR-T cell therapy include optimal supportive care for organ toxicities, high-dose systemic corticosteroids, and anti-cytokine therapies, especially tocilizumab targeting IL-6 [165]. This evidence concerns the gene IL6 and congenital rubella syndrome.